Evaxion Biotech A/S (EVAX): Price and Financial Metrics


Evaxion Biotech A/S (EVAX): $1.61

0.01 (+0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVAX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EVAX Stock Price Chart Interactive Chart >

Price chart for EVAX

EVAX Price/Volume Stats

Current price $1.61 52-week high $3.52
Prev. close $1.60 52-week low $1.41
Day low $1.57 Volume 175,426
Day high $1.65 Avg. volume 779,120
50-day MA $1.85 Dividend yield N/A
200-day MA $2.28 Market Cap 38.37M

Evaxion Biotech A/S (EVAX) Company Bio


Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.


EVAX Latest News Stream


Event/Time News Detail
Loading, please wait...

EVAX Latest Social Stream


Loading social stream, please wait...

View Full EVAX Social Stream

Latest EVAX News From Around the Web

Below are the latest news stories about EVAXION BIOTECH A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.

Evaxion receives FDA fast-track designation for personalized cancer immunotherapy

COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA®.In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial,

Yahoo | January 19, 2023

Evaxion Biotech Gets FDA Approval To Proceed With Clinical Phase 2b Study For EVX-01

Biotech company Evaxion Biotech A/S (EVAX) announced Tuesday that the U.S. Food and Drug Administration or FDA, determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

RTT News | January 3, 2023

Evaxion''s stock soars after getting FDA approval for mid-stage cancer trial

U.S.-listed shares of Evaxion Biotech A/S undefined jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration…

MarketWatch | January 3, 2023

XPEV, LI and BILI are among pre market gainers

Gorilla Technology Group (GRRR) +42%. Chemomab Therapeutics (CMMB) +38% as NASH candidate meets main goal in Phase 2 trial.Evaxion Biotech (EVAX) +21% receives approval from FDA…

Seeking Alpha | January 3, 2023

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. In November

Wallstreet:Online | January 3, 2023

Read More 'EVAX' Stories Here

EVAX Price Returns

1-mo -9.30%
3-mo -36.61%
6-mo -45.79%
1-year -48.73%
3-year N/A
5-year N/A
YTD -9.30%
2022 -59.84%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7352 seconds.